The FDA granted orphan-drug designation to Basilea Pharmaceutica and Astellas Pharma's experimental antifungal isavuconazole as a treatment for invasive aspergillosis. The intravenous and oral-broad spectrum drug is in late-stage studies for severe invasive fungal infections.
Basilea-Astellas' antifungal treatment gets orphan status from FDA
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|